Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 3
1(25.0%)
4Total
Phase 2(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06709014Phase 3Recruiting

A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

Role: collaborator

NCT06394830Phase 2Recruiting

Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)

Role: collaborator

NCT05737121Phase 2Recruiting

Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS

Role: collaborator

NCT03395392Phase 2Completed

NRX-101 for Bipolar Depression With Subacute Suicidal Ideation

Role: collaborator

NCT05779267Unknown

NRX-101 Expanded Access

Role: collaborator

All 5 trials loaded